TY - JOUR
T1 - Cost-effectiveness of school-based asthma screening in an urban setting
AU - Gerald, Joe K.
AU - Grad, Roni
AU - Bailey, William C.
AU - Gerald, Lynn B.
N1 - Funding Information:
Supported by a grant NHLBI 1R01HL65529 from the National Heart, Lung, and Blood Institute .
PY - 2010/3
Y1 - 2010/3
N2 - Background: Much has been done to promote population-based childhood asthma screening; however, concerns remain regarding its cost-effectiveness. Objectives: To conduct a cost-effectiveness analysis of school-based asthma screening strategies. Methods: A 5 health state Markov approach (symptom-free, symptom, exacerbation recovery, emergency department, and hospitalization day) was used to evaluate school-based screening in a simulated population of urban elementary-age school children. Two questionnaire and 2 multistage strategies incorporating spirometry or spirometry with exercise testing were evaluated from the societal perspective by using 365 daily cycles. The outcome was 2006 dollars per quality-adjusted life year (QALY). Results: The most efficient strategy identified children with previously diagnosed but poorly controlled asthma at a cost of $150,000 per QALY (95% CI, $65,800-$318,000). Uncertainty surrounding the cost-effectiveness estimate was primarily a result of the symptom day preference weight estimate (44%), the probability of confirmation after screening (17%), the adequacy of asthma control in the population (9%), and the estimated treatment effect on symptoms (6%). Screening generated an additional 21 symptom-free day equivalents per child identified with previously diagnosed but not well controlled asthma and led to $85.55, $12.36, and $2.58 in additional screening, daily treatment, and indirect costs and $5.01 less in emergency department and hospitalization costs. Conclusion: Population-based asthma screening is not cost-effective at $50,000 per QALY and has only a 20% chance of being cost-effective at $100,000 per QALY. The most efficient approach is to screen for previously diagnosed but poorly controlled asthma. Linking screening with better treatment, and long-term adherence strategies might yield future cost-effective approaches.
AB - Background: Much has been done to promote population-based childhood asthma screening; however, concerns remain regarding its cost-effectiveness. Objectives: To conduct a cost-effectiveness analysis of school-based asthma screening strategies. Methods: A 5 health state Markov approach (symptom-free, symptom, exacerbation recovery, emergency department, and hospitalization day) was used to evaluate school-based screening in a simulated population of urban elementary-age school children. Two questionnaire and 2 multistage strategies incorporating spirometry or spirometry with exercise testing were evaluated from the societal perspective by using 365 daily cycles. The outcome was 2006 dollars per quality-adjusted life year (QALY). Results: The most efficient strategy identified children with previously diagnosed but poorly controlled asthma at a cost of $150,000 per QALY (95% CI, $65,800-$318,000). Uncertainty surrounding the cost-effectiveness estimate was primarily a result of the symptom day preference weight estimate (44%), the probability of confirmation after screening (17%), the adequacy of asthma control in the population (9%), and the estimated treatment effect on symptoms (6%). Screening generated an additional 21 symptom-free day equivalents per child identified with previously diagnosed but not well controlled asthma and led to $85.55, $12.36, and $2.58 in additional screening, daily treatment, and indirect costs and $5.01 less in emergency department and hospitalization costs. Conclusion: Population-based asthma screening is not cost-effective at $50,000 per QALY and has only a 20% chance of being cost-effective at $100,000 per QALY. The most efficient approach is to screen for previously diagnosed but poorly controlled asthma. Linking screening with better treatment, and long-term adherence strategies might yield future cost-effective approaches.
KW - Asthma
KW - Markov modeling
KW - case detection
KW - childhood asthma
KW - cost-effectiveness
KW - economic analysis
KW - quality of life
KW - screening
UR - http://www.scopus.com/inward/record.url?scp=77649258207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77649258207&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2009.12.984
DO - 10.1016/j.jaci.2009.12.984
M3 - Article
C2 - 20226298
AN - SCOPUS:77649258207
SN - 0091-6749
VL - 125
SP - 643-650.e12
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -